Momenta

Investor Relations

NASDAQ: MNTA
Price
11.72
Change
- 0.25
Day High
12.07
Day Low
11.63
Volume
866,300
4:00 PM ET on Dec 19, 2014
Stock price graph

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

In July 2010, the Momenta’s lead product (developed in collaboration with Sandoz) was approved as the first generic version of Lovenox® (Enoxaparin Sodium Injection).  The company’s development pipeline includes a generic version of Copaxone® (glatiramer acetate), also in collaboration with Sandoz, biosimilars in collaboration with Baxter.    necuparanib (formerly M402), a novel oncology drug candidate currently undergoing testing in early phase human clinical trials, and a portfolio of novel autoimmune drug candidates.

View Annual Report and Proxy Material

View all »   RSSRecent Releases

Dec 1, 2014
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer

Dec 1, 2014
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)

Nov 24, 2014
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank BioFEST

Last Revised 6/12/2012